Global Drug R&D Express (Apr. 2023)

Based on the latest data from SYNAPSE, we has released the "Global Drug R&D Express (Apr. 2023)". The report includes a total of 53 drugs consisting of: ◉ 8 drugs first approved globally: 2 Prophylactic vaccine, 2 Small molecule drug (SMD), 1 Monoclonal antibody(mAb), 1 Hematopoietic stem cell, 1 Oligonucleotide antisense, 1 Live biotherapeutic products. ◉ 45 drugs under Expedited Review pathways worldwide: 16 Orphan Drug designation, 12 Fast Track designation, 6 Breakthrough Therapy designation, 4 Priority review, 2 Rare Pediatric Disease designation, 2 Innovative Licensing and Access Pathway (ILAP), 1 Accelerated Approval, 1 Emergency Use Authorization, 1 PRIME (EU). The report also highlights: ◼ 5 first approved drugs: Vilobelimab、R21/Matrix-M、Omidubicel、Reassortant Rotavirus Vaccine、AKEEGA. ◼ 7 Expedited Review Pathway drugs: Remternetug、Sibeprenlimab、HH-003、FCN-159、SAB-176、Resmetirom、CB-011. providing a comprehensive analysis of each, including their snapshot, R&D status, active patents, mechanisms of action, clinical trial information, and competitive landscape.